MedTrace Logo

Cardiotoxicities in Patients Receiving BTKi

NCT05521178 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with CLL patients who are initiating treatment with a Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or acalabrutinib.

Conditions

Interventions

DIAGNOSTIC_TEST

Electrocardiogram

ECG to monitor electrical activities of the heart on each visit

DIAGNOSTIC_TEST

Echocardiogram

Echocardiogram at baseline and 6 months

DIAGNOSTIC_TEST

Cardiac magnetic resonance imaging

Cardiac MRI at baseline and 6 months

DEVICE

Mobile cardiac telemetry

Mobile cardiac telemetry at baseline and 6 months

DIAGNOSTIC_TEST

Blood pressure monitoring

Home blood pressure monitoring three times per week

DIAGNOSTIC_TEST

Blood draw

Blood draw at baseline, 3 and 6 months

Sponsors & Collaborators

Principal Investigators

  • Inhye Ahn, MD · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2026-01-01
Completion
2028-01-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05521178 on ClinicalTrials.gov